Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Unexpected cause of vemurafenib-induced nephrotoxicity: ferrochelatase

Published:2021-12 Issue:6 Volume:100 Page:1158-1160
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Yamada Ryo,Yanagita Motoko^ORCID

Funder

Mitsubishi Tanabe Pharma Corporation

Boehringer Ingelheim

Kyowa Hakko Kirin

Publisher

Elsevier BV

Subject

Nephrology

Reference9 articles.

1. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer;Porta;Kidney Int,2020

2. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond;Holderfield;Nat Rev Cancer,2014

3. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib;Jhaveri;JAMA Oncol,2015

4. Bai Y, Kim JY, Bisunke B, et al. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int. 2021;100:1214–1226.

5. Chemical proteomics reveals ferrochelatase as a common off-target of kinase inhibitors;Klaeger;ACS Chem Biol,2016

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioactivation and reactivity research advances – 2022 year in review‡;Drug Metabolism Reviews;2023-08-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP